New breast cancer treatment aims to match Chemo's power with fewer harsh side effects
NCT ID NCT06107673
Summary
This study is testing whether a new drug combination (dalpiciclib plus hormone therapy) works as well as standard chemotherapy for shrinking certain breast cancers before surgery. It will involve 144 postmenopausal women with ER-positive, HER2-negative breast cancer. The main goal is to see if the new approach is similarly effective but safer and easier to tolerate than chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050011, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.